Current Report Filing (8-k)
December 16 2020 - 5:01PM
Edgar (US Regulatory)
0001621227
false
00-0000000
0001621227
2020-12-16
2020-12-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): December 16, 2020
ADAPTIMMUNE THERAPEUTICS PLC
(Exact name of registrant as specified
in its charter)
England and Wales
|
|
1-37368
|
|
Not Applicable
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
60 Jubilee Avenue, Milton Park
Abingdon, Oxfordshire OX14 4RX
United Kingdom
(Address of principal executive offices,
including zip code)
(44) 1235 430000
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which registered
|
American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share
|
|
ADAP
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 16, 2020 Adaptimmune Therapeutics plc (the “Company”)
promoted Elliot Norry, Chief Medical Officer, to its executive team effective from January 1, 2021.
In connection with his promotion, on
December 16, 2020, Dr. Norry entered into an employment agreement (the “Employment Agreement”) with the Company’s
U.S. subsidiary, Adaptimmune LLC (the “Employer”). Under the terms of the Employment Agreement, effective January 1,
2021, Dr. Norry will receive an annual base salary of $425,100, which may be modified by the Employer in its sole discretion. In
addition to the base salary, Dr. Norry will be eligible to receive an annual discretionary bonus following the end of each calendar
year that ends during his employment period when he serves as Chief Medical Officer (“Annual Bonus”), subject to: (i)
objective criteria set forth by the Board or an authorized delegate thereof on an annual basis; and (ii) the overall performance
of the Company. The initial target Annual Bonus effective from January 1, 2021 will be forty-five percent of Dr. Norry’s
base salary. The Annual Bonus payment will be pro-rated for any partial year of service.
Dr. Norry will also be eligible to
participate in the equity plans sponsored and/or maintained by the Company and its affiliates from time to time, in accordance
with the terms of any such plans, at the sole and absolute discretion of the Company and the Board or the remuneration committee.
On such date as the Board or the remuneration committee may determine and subject to the rules of the relevant equity plan and
any applicable legal or regulatory requirements, Dr. Norry will be awarded market value options to acquire ordinary shares in the
Company and RSU-style options to acquire ordinary shares in the Company on the condition that, at the time of the award of such
stock options, Dr. Norry continues to serve as the Company’s Chief Medical Officer and remains employed by the Company and
is not under notice of termination (given or received). The options will vest over a period of four years from the date of grant.
The market value options will have an exercise price per ordinary share of not less than one sixth of the closing trading price
of the Company’s American Depositary Shares on the last business day prior to the date of grant, translated from USD to GBP,
and the RSU-style options will have an exercise price of £0.001 per ordinary share. Dr. Norry will also be entitled to additional
employee benefits.
The Company may terminate Dr. Norry’s
employment with or without cause and without notice, but Dr. Norry is required to provide at least 60 days’ advance written
notice to the Company in order to terminate his employment. In the event of a termination of employment by the Company without
cause or a resignation by Dr. Norry for good reason, upon a change of control, any portion of stock option awards that were granted
and unvested as of the date of termination will vest and immediately become exercisable on the date of termination. Dr. Norry will
also be entitled to payments under the Company’s executive severance policy in the event of a termination by the Company
without cause or a resignation by Dr. Norry for good reason without a change of control and upon a change of control. In order
to receive severance benefits under the policy, Dr. Norry is required to execute a release of claims in favor of the Company and
comply with certain other post-employment covenants set forth in the Employment Agreement. The Employment Agreement also contains
non-solicitation and non-competition provisions for a twelve month period as well as standard confidentiality provisions.
The foregoing summary of the Employment
Agreement is qualified in its entirety by reference to the complete text of the Employment Agreement, a copy of which is filed
as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
ADAPTIMMUNE THERAPEUTICS PLC
|
|
|
|
|
|
Date: December 16, 2020
|
By:
|
/s/ Margaret Henry
|
|
|
Name:
|
Margaret Henry
|
|
|
Title:
|
Corporate Secretary
|
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024